Analystreport

Kiniksa Pharmaceuticals Ltd (NASDAQ: KNSA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock.

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares  (KNSA) 
Last kiniksa pharmaceuticals, ltd. - class a ordinary shares earnings: 8/12 04:02 pm Check Earnings Report